teaser
According to a report by Pharmalive, the European Commission has approved sodium oxybate (Xyrem®) for treating narcolepsy with cataplexy in adult patients.
↓Article continues below this sponsored advert↓
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE
↑Advertisement↑
Narcolepsy is a disorder which typically begins with excessive daytime sleepiness during the second and third decades of life, progressing to include disturbed night-time sleep, cataplexy, sleep paralysis and hypnagogic hallucinations (hallucinations while falling asleep).
The most commonly reported adverse drug reactions with sodium oxybate are dizziness, nausea, and headache, all occurring in 10% to 20% of patients.
National Electronic Library for Medicines 13/03/2007
